Sponsored by: Investment Center

Something new in your business?  Click here to submit your business press release

Chamber Corner | Main Street News | Job Hunt | Classifieds | Calendar | Illinois Lottery 

BioMarin to buy Prosensa in $840 million deal

Send a link to a friend  Share

[November 24, 2014]  (Reuters) - BioMarin Pharmaceuticals Inc said it would buy Dutch drug developer Prosensa Holding NV for about $840 million including milestone payments, aiming to add to its portfolio of drugs to treat rare diseases.

The acquisition will give BioMarin worldwide rights to several orphan-drug candidates including drisapersen, which is being developed to treat Duchenne muscular dystrophy (DMD), a rare muscle degeneration disease.

Drisapersen could be the first approved treatment for the rare genetic disease that affects one in 3,600 newborn boys, most of whom die by age 30.

BioMarin will offer $17.75 for every Prosensa share and make two milestone payments of $80 million each following U.S. and European approvals for Prosensa's lead drug, drisapersen.

Excluding milestone payments, the offer represents a premium of 55 percent to Prosensa's last closing price of $11.44.

Prosensa's shares were trading at $18.50 premarket on Monday.

Prosensa has filed for marketing approval of drisapersen, stealing a march on rival Sarepta Therapeutics Inc, which is conducting mid-stage studies for its DMD drug eteplirsen.

Sarepta received a major setback last month when U.S. regulators asked for more data on eteplirsen, a move that could delay the drug further.

Wedbush Securities analyst Liana Moussatos said the deal made sense for BioMarin, given its history with developing drugs for the indication.

The company dropped its own DMD candidate in 2010, after the drug failed early-stage studies. (http://reut.rs/1viCDST)

[to top of second column]

Both Sarepta and Prosensa from use the same mechanism in their DMD treatments. The drugs skip a faulty section of a gene to produce a protein called dystrophin, the lack of which causes the disease.

Prosensa is developing two other DMD drugs, which are currently being tested in early and mid-stage studies. It is also testing drugs to treat Huntington's disease.

BioMarin's shares were unchanged before the bell.

(Reporting by Vidya L Nathan and Amrutha Penumudi in Bangalore; Editing by Saumyadeb Chakrabarty)

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Back to top